A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)

Trial Profile

A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Momotaro-Gene
  • Most Recent Events

    • 23 Mar 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 23 Mar 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.
    • 29 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top